

Product Data Sheet

PD-1/PD-L1 antagonist 1

Cat. No.: HY-158052

 $\begin{tabular}{ll} \begin{tabular}{ll} \be$


Molecular Weight: 955.88

Target: PD-1/PD-L1

Pathway: Immunology/Inflammation

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.



BIOLOGICAL ACTIVITY

BIOLOGICAL ACTIV		
Description	PD-1/PD-L1 antagonist 1 (Compound A5) is an antagonist for programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) interaction, with an IC $_{50}$ of 23.78 nM $^{[1]}$.	
IC ₅₀ & Target	23.78 nM (PD-1/PD-L1 interaction)	
In Vitro	PD-1/PD-L1 antagonist 1 (0-3 μ M) dose-dependently inhibits PD-1 and PD-L1 interaction in a co-system of Jurkat-NFAT-PD-1 cells and Hep3B-OS8-hPD-L1 cells, exhibits no significant cytotoxicity in Jurkat cells with a safe dose of 3.3 μ M ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity Assay ^[1]	
	Cell Line:	Jurkat
	Concentration:	0-30 μΜ
	Incubation Time:	48 h
	Result:	Maintained the cell viability with concentration less than 3.3 $\mu M.$ Reduced cell viability at 10 and 30 $\mu M.$

REFERENCES

[1]. Wu X, et al. Design, Synthesis, and Evaluation of 8-(o-Tolyl) quinazoline Derivatives as Small-Molecule PD-1/PD-L1 Antagonists[J]. ACS Medicinal Chemistry Letters, 2024.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA